

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
11 March 2004 (11.03.2004)

PCT

(10) International Publication Number
WO 2004/020011 A1

(51) International Patent Classification⁷: A61L 24/00,
24/02, 27/50, 31/18, 31/14, 31/02, A61K 49/18

(74) Agent: DALEY, Sean, P.; Fish & Richardson P.C., 225
Franklin Street, Boston, MA 02110-2804 (US).

(21) International Application Number:
PCT/US2003/027358

(22) International Filing Date: 29 August 2003 (29.08.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10/232,265 30 August 2002 (30.08.2002) US

(71) Applicant: SCIMED LIFE SYSTEMS, INC. [US/US];
One Scimed Place, Maple Grove, MN 55331-1566 (US).


(72) Inventors: RIOUX, Robert, F.; 20 Woodridge Lane, Ash-
land, MA 01721 (US). CASEY, Thomas, V., II; 67 Sunrise
Avenue, Grafton, MA 01519 (US). LANPHERE, Janel;
76 Cloverdale Road, Newton, MA 02461 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: EMBOLIZATION



(57) Abstract: A particle includes a ferromag-
netic material, a radiopaque material, and/or an
MRI-visible material.



Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Embolization

TECHNICAL FIELD

This invention relates to embolization.

BACKGROUND

Therapeutic vascular occlusions (embolizations) are used to prevent or treat pathological conditions *in situ*. Compositions including embolic particles are used for occluding vessels in a variety of medical applications. Delivery of embolic particles through a catheter is dependent on size uniformity, density and compressibility of the embolic particles.

SUMMARY

In one aspect, the invention features a particle that includes a polymeric matrix and a ferromagnetic material distributed in the polymeric matrix. The particle has a diameter of from about ten microns to about 3,000 microns.

In another aspect, the invention features a method of manufacturing particles. The method includes forming a mixture containing a polymer, a gelling compound, and a ferromagnetic material, and treating the mixture to form a particle that includes the polymeric matrix and the ferromagnetic material in the polymeric matrix. The particles have a mean diameter of from about ten microns to about 3,000 microns.

In a further aspect, the invention features a method that includes administering to a subject a therapeutically effective amount of embolic particles. The particles include a polymeric matrix and a ferromagnetic material distributed in the polymeric matrix. The particles have a mean diameter of from about ten microns to about 3,000 microns.

In one aspect, the invention features a particle that includes a polymeric matrix and a radiopaque material distributed in the polymeric matrix. The particle has a diameter of from about ten microns to about 3,000 microns. The particle has an interior with a density of large pores and a surface region with a density of large pores, and the density of large pores of the interior is greater than the density of large pores of the surface region.

In another aspect, the invention features a method of manufacturing particles. The method includes forming a mixture containing a polymer, gelling compound, and a radiopaque material, and treating the mixture to form a particle comprising a polymeric matrix and radiopaque material in the polymeric matrix. The particles have a diameter of from about ten microns to about 3,000 microns. The particles have an interior with a density of large pores and a surface region with a density of large pores, and the density of large pores of the interior is greater than the density of large pores of the surface region.

In a further aspect, the invention features a method that includes administering to a subject a therapeutically effective amount of embolic particles. The particles include a polymeric matrix and a radiopaque material distributed in the polymeric matrix. The particles have a mean diameter of from about ten microns to about 3,000 microns. The particles have an interior with a density of large pores and a surface region with a density of large pores, and the density of large pores of the interior is greater than the density of large pores of the surface region.

In one aspect, the invention features a particle that includes a polymeric matrix and an MRI-visible material distributed in the polymeric matrix. The particle has a diameter of from about ten microns to about 3,000 microns. The particle has an interior with a density of large pores and a surface region with a density of large pores, and the density of large pores of the interior is greater than the density of large pores of the surface region.

In another aspect, the invention features a method of manufacturing particles. The method includes forming a mixture containing a polymer, gelling compound, and an MRI-visible material, and treating the mixture to form a particle comprising a polymeric matrix and the MRI-visible material in the polymeric matrix. The particles have a mean diameter of from about ten microns to about 3,000 microns. The particles have an interior with a density of large pores and a surface region with a density of large pores, and the density of large pores of the interior is greater than the density of large pores of the surface region.

In a further aspect, the invention features a method that includes administering to a subject a therapeutically effective amount of embolic particles. The particles include a polymeric matrix and an MRI-visible material distributed in the polymeric

matrix. The particles have a mean diameter of from about ten microns to about 3,000 microns. The particles have an interior with a density of large pores and a surface region with a density of large pores, and the density of large pores of the interior is greater than the density of large pores of the surface region.

5 In another aspect, the invention features a method that includes heating a plurality of particles disposed in a body lumen. The particles include a polymeric matrix and a ferromagnetic material distributed in the polymeric matrix. The particles have a diameter of from about ten microns to about 3,000 microns.

Embodiments can include one or more of the following.

10 A ferromagnetic material can be, for example, a metal (e.g., a transition metal), a metal alloy, a metal oxide, a soft ferrite, a rare-earth magnet alloy, or an amorphous and non-earth alloy. Examples of ferromagnetic materials include magnetite, nickel, cobalt, iron and Mu-metal.

A radiopaque material can be, for example, a metal, a metal alloy, a metal
15 oxide, or a contrast agent. Examples of radiopaque materials include titanium dioxide, bismuth subcarbonate, platinum and barium sulfate.

An MRI-visible material can be, for example, a non-ferrous metal-alloy containing paramagnetic elements, a non-ferrous metallic band coated with an oxide or a carbide layer of dysprosium or gadolinium, a non-ferrous metal coated with a
20 layer of superparamagnetic material, or a nanocrystalline particle of a transition metal oxide. Examples of MRI-visible materials include terbium-dysprosium, dysprosium, gadolinium, Dy_2O_3 , and gadolinium-containing compounds (e.g., Gd_2O_3).

The material (ferromagnetic material, radiopaque material, MRI-visible material) can be in the shape of a particle.

25 The material (ferromagnetic material, radiopaque material, MRI-visible material) can have a diameter of from about two microns to about 20 microns (e.g., from about ten microns to about 12 microns).

The material (ferromagnetic material, radiopaque material, MRI-visible material) can be substantially homogeneously distributed in the polymeric matrix.

30 A particle containing a polymer matrix and a material (ferromagnetic material, radiopaque material, MRI-visible material) can have a diameter of at least about 100 microns (e.g., at least about 500 microns, at least about 1,000 microns, at least about

1,500 microns, at least about 2,000 microns, at most about 2,500 microns) and/or at most about 2,000 microns (e.g., at most about 1,500 microns, at most about 1,200 microns, at most about 1,000 microns, at most about 500 microns). For example, such a particle can have a diameter of from about 100 microns to about 500 microns, or from about 500 microns to about 1,200 microns.

A particle containing a polymer matrix and a material (ferromagnetic material, radiopaque material, MRI-visible material) can also include a therapeutic agent (e.g., in the particle and/or on the particle).

A particle containing a polymer matrix and a material (ferromagnetic material, radiopaque material, MRI-visible material) can be substantially spherical.

The polymeric matrix can include a polysaccharide (e.g., alginate).

The polymeric matrix can be formed of one or more polyvinyl alcohols, polyacrylic acids, polymethacrylic acids, poly vinyl sulfonates, carboxymethyl celluloses, hydroxyethyl celluloses, substituted celluloses, polyacrylamides, polyethylene glycols, polyamides, polyureas, polyurethanes, polyesters, polyethers, polystyrenes, polysaccharides, polylactic acids, polyethylenes, polymethylmethacrylates, polycaprolactones, polyglycolic acids, and/or poly(lactic-co-glycolic) acids.

A particle containing a polymer matrix and a material (ferromagnetic material, radiopaque material, MRI-visible material) can include two or more polymers. For example, one of the polymers can form a coating over another (e.g., matrix) polymer. The polymer coating can contain one or more ferromagnetic materials, one or more MRI-visible materials and/or one or more radiopaque materials. The density of the material(s) in the coating can be less than, greater than, or about the same as the density of the material(s) in the matrix polymer. The polymer coating can be bioabsorbable (e.g., formed of a polysaccharide such as alginate).

In some embodiments, a particle containing a polymeric matrix and a ferromagnetic material can contain pores. In certain embodiments, a particle containing a polymeric matrix and a ferromagnetic material can be nonporous.

In some embodiments in which a particle that contains a polymeric matrix and a ferromagnetic material contains pores, the density of large pores in an interior

region of the particle can be greater than the density of large pores of the surface region.

5 A particle containing a polymer matrix and a material (ferromagnetic material, radiopaque material, MRI-visible material) can contain from about 0.1 percent to about 90 percent by weight (e.g., from about 0.1 percent to about 75 percent by weight) of the ferromagnetic material, MRI-visible material or radiopaque material.

A particle containing a polymer matrix and a material (ferromagnetic material, radiopaque material, MRI-visible material) can have a coating that includes an inorganic, ionic salt.

10 The gelling compound used in a method to make a particle can be a polysaccharide (e.g. alginate).

A method of making a particle can include forming drops of the mixture that contains the polymer and gelling agent. The method can include contacting the drops with a gelling agent. The method can further include reacting the polymer. The method can also include removing the gelling compound. The method can include combining the particles with a pharmaceutically acceptable medium.

A method of administering embolic particles can include administration by percutaneous injection.

20 A method of administering embolic particles can include administration by a catheter.

A method of administering embolic particles can include applying a magnetic field to direct the particles. The magnetic field can be external to a subject, internal to the subject, or both. The particles can be directed with a catheter comprising a magnet.

25 A method of administering embolic particles can include releasing the therapeutic agent from the particles.

A method can include ablating body tissue.

In some embodiments, heating the particles can include exposing the particles to RF radiation.

30 In some embodiments, heating the particles heats body tissue.

Embodiments of the invention may have one or more of the following advantages.

In some embodiments, a particle can contain one or more components that are biocompatible. As an example, a particle can include one or more biocompatible polymers (e.g., one or more bioabsorbable polymers). As another example, a particle can contain one or more materials (e.g., one or more radiopaque materials, one or more ferromagnetic materials, one or more MRI-visible materials) that are biocompatible. In certain embodiments, a particle can include one or more biocompatible polymers (e.g., one or more bioabsorbable polymers) and one or more additional biocompatible materials (e.g., one or more radiopaque materials, one or more ferromagnetic materials, one or more MRI-visible materials).

In embodiments in which a particle contains one or more radiopaque materials, the particle can exhibit enhanced visibility under X-ray fluoroscopy (e.g., when the particle is in a subject). In certain embodiments, the presence of one or more radiopaque materials can allow the particle to be viewed using X-ray fluoroscopy in the absence of a radiopaque contrast agent. This can allow a physician or technician to view the particle in an embolic composition (e.g., prior to delivering the particles from a catheter) via a non-invasive technique, allow the physician or technician to position the particles at a desired location within the subject (e.g., by positioning the delivery portion of the catheter at a desired location within the subject and then delivering the embolic composition into the subject), and/or allow the physician or technician to monitor the progress of a procedure and/or determine whether the particles are migrating to a site that is not targeted for treatment.

In embodiments in which a particle contains one or more MRI-visible materials, the particle can exhibit enhanced visibility under MRI (e.g., when the particle is in a subject). In certain embodiments, the presence of one or more MRI-visible materials can allow the particle to be viewed using MRI in the absence of an MRI contrast agent. This can allow a physician or technician to view the particle in an embolic composition (e.g., prior to delivering the particles from a catheter) via a non-invasive technique, allow the physician or technician to position the particles at a desired location within the subject (e.g., by positioning the delivery portion of the catheter at a desired location within the subject and then delivering the embolic composition into the subject), and/or allow the physician or technician to monitor the

progress of a procedure and/or determine whether the particles are migrating to a site that is not targeted for treatment.

In embodiments in which a particle contains one or more ferromagnetic materials, the positioning of the particle can be relatively easily and/or non-invasively controlled using a magnetic field (e.g., a magnetic field outside a subject, a magnetic field inside a subject, or both). As an example, the particle can be steered through a body lumen (e.g., to a relatively distal location of a lumen that might otherwise be difficult for the particle to reach) by applying a magnetic field to the particle. As another example, the ability of the particle to migrate from a desired location can be reduced by applying a magnetic field.

In some embodiments (e.g., when a particle contains a ferromagnetic material), the particle can enhance RF ablation procedures.

Features and advantages are in the description, drawings, and claims.

DESCRIPTION OF DRAWINGS

FIG. 1 is a cross-sectional view of an embodiment of a particle.

FIG. 2A is a schematic of an embodiment of a system for manufacturing particles, and FIG. 2B is an enlarged schematic of region 2B in FIG. 2A.

FIG. 3A is a schematic illustrating an embodiment of injection of an embolic composition including embolic particles into a vessel, and FIG. 3B is an enlarged view of the region 3B in FIG. 3A.

DETAILED DESCRIPTION

Referring to FIG. 1, a substantially spherical particle 10 includes a matrix 12, a material 14 and pores 16. Material 14, which is formed of one or more radiopaque materials, one or more MRI-visible materials, and/or one or more ferromagnetic materials, is substantially homogeneously distributed in matrix 12. Pores 16 are regions of particle 10 that are substantially devoid of matrix 12 and material 14. In some embodiments, pores 16 contain a gas, such as air.

In general, particle 10 has a diameter of about 3,000 microns or less (e.g., about 2,500 microns or less; about 2,000 microns or less; about 1,500 microns or less; about 1,200 microns or less; about 1,000 microns or less; about 900 microns or less;

about 700 microns or less; about 500 microns or less; about 400 microns or less;
about 300 microns or less; about 100 microns or less) and/or about ten microns or
more (e.g., about 100 microns or more; about 300 microns or more; about 400
microns or more; about 500 microns or more; about 700 microns or more; about 900
5 microns or more; about 1,000 microns or more; about 1,200 microns or more; about
1,500 microns or more; about 2,000 microns or more; about 2,500 microns or more).
In certain embodiments, the diameter of particle 10 can be from about 100 microns to
about 700 microns; from about 500 microns to about 700 microns; from about 100
microns to about 500 microns; from about 100 microns to about 300 microns; from
10 about 300 microns to about 500 microns; from about 500 microns to about 1,200
microns; from about 500 microns to about 700 microns; from about 700 microns to
about 900 microns; from about 900 microns to about 1,200 microns.

As shown in FIG. 1, particle 10 can be considered to include a center region,
C, from the center c' of particle 10 to a radius of about $r/3$, a body region, B, from
15 about $r/3$ to about $2r/3$, and a surface region, S, from about $2r/3$ to r . The regions can
be characterized by the relative size of pores 16 present in particle 10 in each region,
the density of pores 16 (the number of pores 16 per unit volume of particle 10) in each
region, and/or the mass density (the density of the matrix 12 and material 14 mass per
unit volume of particle 10) in each region.

20 In general, the mean size of pores 16 in region C of particle 10 is greater than
the mean size of pores 16 at region S of particle 10. In some embodiments, the mean
size of pores 16 in region C of particle 10 is greater than the mean size of pores 16 in
region B particle 10, and/or the mean size of pores 16 in region B of particle 10 is
greater than the mean size of pores 16 at region S particle 10. In some embodiments,
25 the mean size of pores 16 in region C is about 20 microns or more (e.g., about 30
microns or more, from about 20 microns to about 35 microns). In certain
embodiments, the mean size of pores 16 in region B is about 18 microns or less (e.g.
about 15 microns or less, from about 18 microns to about two microns). In some
embodiments, the mean size of pores 16 in region S is about one micron or less (e.g.
30 from about 0.1 micron to about 0.01 micron). In certain embodiments, the mean size
of pores 16 in region B is from about 50 percent to about 70 percent of the mean size
of pores 16 in region C, and/or the mean size of pores 16 at region S is about ten

percent or less (e.g., about two percent or less) of the mean size of pores 16 in region B. In some embodiments, the surface of particle 10 and/or its region S is/are substantially free of pores having a diameter greater than about one micron (e.g., greater than about ten microns). In certain embodiments, the mean size of pores 16 in the region from $0.8r$ to r (e.g., from $0.9r$ to r) is about one micron or less (e.g., about 0.5 micron or less, about 0.1 micron or less). In some embodiments, pores 16 in the region from the center of particle 10 to $0.9r$ (e.g., from the center of particle 10 to $0.8r$) are about ten microns or greater and/or have a mean size of from about two microns to about 35 microns. In certain embodiments, the mean size of pores 16 in the region from $0.8r$ to r (e.g., from $0.9r$ to r) is about five percent or less (e.g., about one percent or less, about 0.3 percent or less) of the mean size of pores 16 in the region from the center to $0.9r$. In some embodiments, the largest pores in particle 10 can have a size in the range of about one percent or more (e.g., about five percent or more, about ten percent or more) of the diameter of particle 10. The size of pores 16 in particle 10 can be measured by viewing a cross-section of particle 10. For irregularly shaped (nonspherical) pores, the maximum visible cross-section is used.

Generally, the density of pores 16 in region C of particle 10 is greater than the density of pores 16 at region S of particle 10. In some embodiments, the density of pores 16 in region C of particle 10 is greater than the density of pores 16 in region B of particle 10, and/or the density of pores 16 in region B of particle 10 is greater than the density of pores 16 at region S of particle 10.

In general, the mass density in region C of particle 10 is less than the mass density at region S of particle 10. In some embodiments, the mass density in region C of particle 10 is less than the mass density in region B of particle 10, and/or the mass density in region B of particle 10 is less than the mass density at region S of particle 10.

In general, the density of particle 10 (e.g., as measured in grams of material per unit volume) is such that it can be readily suspended in a carrier fluid (e.g., a pharmaceutically acceptable carrier, such as a saline solution, a contrast solution, or a mixture thereof) and remain suspended during delivery. In some embodiments, the density of particle 10 is from about 1.1 grams per cubic centimeter to about 1.4 grams per cubic centimeter. As an example, for suspension in a saline-contrast solution, the

density of particle 10 can be from about 1.2 grams per cubic centimeter to about 1.3 grams per cubic centimeter.

5 In certain embodiments the region of small pores near the surface of particle 10 can be relatively stiff and incompressible, which can enhance resistance to shear forces and abrasion. In addition, the variable pore size profile can produce a symmetric compressibility and, it is believed, a compressibility profile. As a result, particle 10 can be relatively easily compressed from a maximum, at rest diameter to a smaller, compressed first diameter. Compression to an even smaller diameter, however, may involve substantially greater force. Without wishing to be bound by theory, it is believed that a variable compressibility profile can be the result of a relatively weak, collapsible inter-pore wall structure in the center region of particle 10 (where the pores are relatively large), and a stiffer inter-pore wall structure near the surface of particle 10 (where the pores are more numerous and relatively small). It is further believed that a variable pore size profile can enhance elastic recovery after compression. It is also believed that the pore structure can influence the density of particle 10 and the rate of carrier fluid or body fluid uptake.

15 In some embodiments, a plurality of the particles (e.g., in an embolic composition) can be delivered through a catheter having a lumen with a cross-sectional area that is smaller (e.g., about 50 percent or less) than the uncompressed cross-sectional area of the particles. In such embodiments, the particles are compressed to pass through the catheter for delivery into the body. Typically, the compression force is provided indirectly, by depressing the syringe plunger to increase the pressure applied to the carrier fluid. In general, the particles are relatively easily compressed to diameters sufficient for delivery through the catheter into the body. The relatively robust, rigid surface region of the particles can resist abrasion when the particles contact hard surfaces such as syringe surfaces, hard plastic or metal stopcock surfaces, and/or the catheter lumen wall (made of, e.g., Teflon) during delivery. Once in the body, the particles can substantially recover to original diameter and shape for efficient transport in the carrier and body fluid stream. At the point of occlusion, the particles can again compress as they aggregate in the occlusion region. The particles can form a relatively dense occluding mass. The compression of the particles in the body is generally determined by the force provided

by body fluid flow in the lumen. In some embodiments, the compression may be limited by the compression profile of the particles, and the number of particles needed to occlude a given diameter may be reduced.

5 In certain embodiments, the sphericity of particle 10 after compression in a catheter (e.g., after compression to about 50 percent or more of the cross-sectional area of particle 10) is about 0.8 or more (e.g., about 0.85 or more, about 0.9 or more, about 0.95 or more, about 0.97 or more). Particle 10 can be, for example, manually compressed, essentially flattened, while wet to about 50 percent or less of its original diameter and then, upon exposure to fluid, regain a sphericity of about 0.8 or more
10 (e.g., about 0.85 or more, about 0.9 or more, about 0.95 or more, about 0.97 or more). As referred to herein, the sphericity of a particle is calculated using the equations in Appendix A. The relevant parameters of a particle can be determined using a Beckman Coulter RapidVUE Image Analyzer version 2.06 (Beckman Coulter, Miami, FL).

15 Porous particles are described, for example, in U.S. Patent Application No. _____ [Attorney Docket No. 01194-465001], filed on August 8, 2003, and entitled "Embolization", which is incorporated herein by reference.

In general, matrix 12 is formed of one or more polymers. Examples of polymers include polyvinyl alcohols, polyacrylic acids, polymethacrylic acids, poly
20 vinyl sulfonates, carboxymethyl celluloses, hydroxyethyl celluloses, substituted celluloses, polyacrylamides, polyethylene glycols, polyamides, polyureas, polyurethanes, polyesters, polyethers, polystyrenes, polysaccharides, polylactic acids, polyethylenes, polymethylmethacrylates, polycaprolactones, polyglycolic acids, poly(lactic-co-glycolic) acids (e.g., poly(d-lactic-co-glycolic) acids), and copolymers
25 or mixtures thereof. In some embodiments, matrix 12 can be substantially formed of a highly water insoluble, high molecular weight polymer. An example of such a polymer is a high molecular weight polyvinyl alcohol (PVA) that has been acetalized. Matrix 12 can be substantially pure intrachain 1,3-acetalized PVA and substantially free of animal derived residue such as collagen. In some embodiments, particle 10
30 includes a minor amount (e.g., about 2.5 weight percent or less, about one weight percent or less, about 0.2 weight percent or less) of a gelling material (e.g., a polysaccharide, such as alginate). In certain embodiments, the majority (e.g., at least

about 75 weight percent, at least about 90 weight percent, at least about 95 weight percent) of matrix 12 is formed of a bioabsorbable polymer (e.g., polysaccharide, such as alginate).

In general, the amount of matrix 12 contained in particle 10 can be varied as desired. In some embodiments, particle 10 can include about 99.9 percent by weight or less (e.g., about 99.5 percent by weight or less, about 99 percent by weight or less, about 95 percent by weight or less, about 90 percent by weight or less, about 80 percent by weight or less, about 70 percent by weight or less, about 60 percent by weight or less, about 50 percent by weight or less, about 40 percent by weight or less, about 30 percent by weight or less, about 20 percent by weight or less) and/or about ten percent by weight or more (e.g., about 20 percent by weight or more, about 30 percent by weight or more, about 40 percent by weight or more, about 50 percent by weight or more, about 60 percent by weight or more, about 70 percent by weight or more, about 80 percent by weight or more, about 90 percent by weight or more, about 95 percent by weight or more) of matrix 12.

In some embodiments, material 14 is formed of one or more ferromagnetic materials. As used herein, a ferromagnetic material refers to a material that has a magnetic susceptibility of at least about 0.075 or more (e.g., at least about 0.1 or more; at least about 0.2 or more; at least about 0.3 or more; at least about 0.4 or more; at least about 0.5 or more; at least about one or more; at least about ten or more; at least about 100 or more; at least about 1,000 or more; at least about 10,000 or more) when measured at 25°C. A ferromagnetic material can be, for example, a metal (e.g., a transition metal such as nickel, cobalt, or iron), a metal alloy (e.g., a nickel-iron alloy such as Mu-metal), a metal oxide (e.g., an iron oxide such as magnetite), a ceramic nanomaterial, a soft ferrite (e.g., nickel-zinc-iron), a magnet alloy (e.g., a rare earth magnet alloy such as a neodymium-iron-boron alloy or a samarium-cobalt alloy), an amorphous alloy (e.g., iron-silicon-boron), a non-earth alloy, or a silicon alloy (e.g., an iron-zirconium-copper-boron-silicon alloy, an iron-zirconium-copper-boron-silicon alloy). Magnetite is commercially available from FerroTec Corporation (Nashua, NH), under the tradename EMG 1111 Ferrofluid. Iron-copper-niobium-boron-silicon alloys are commercially available from Hitachi Metals of America

under the tradename Finemet™. Iron-zirconium-copper-boron-silicon alloys are commercially available from MAGNETEC GmbH under the tradename Nanoperm®.

5 In embodiments in which material 14 is a ferromagnetic material, a magnetic source can be used to move or direct the particles to a treatment site (see discussion below). The magnetic source can be external to the subject's body, or can be used internally. In some cases, both an external magnetic source and an internal magnetic source can be used to move the particles. An example of an internal magnetic source is a magnetic catheter. Magnetic catheters are described in U.S. Patent Application No. 10/108,874, filed on March 29, 2002, and entitled "Magnetically Enhanced
10 Injection Catheter", which is incorporated herein by reference. An example of an external magnetic source is a magnetic wand.

In some embodiments in which material 14 is a ferromagnetic material, the particles can be used to enhance the effects of an ablation procedure (e.g., an RF ablation procedure). For example, the particles can be used to enhance the ablation of
15 a tumor. First, an RF probe (e.g., a 3.5 centimeter coaxial LeVeen electrode, available from RadioTherapeutics, Mountain View, CA) having tines at one end can be inserted into the area of the tumor. The particles can then be delivered to the area around the tines of the RF probe by, e.g., a catheter or a syringe. Thereafter, the tines can be deployed and the RF probe can be activated so that RF energy flows through
20 the tines, thereby heating the tissue around the tines. Eventually, the tumor tissue can die as a result of the heating. Because they include ferromagnetic material, which can be relatively conductive, the particles can enhance the effects of ablation. For example, the circuit can be maintained for a longer period of time, resulting, e.g., in an increase in the area of the ablated surface. The end of the ablation period can be
25 defined, for example, by the temperature of the ablated tissue or by the measured impedance of the circuit.

In certain embodiments in which material 14 is a ferromagnetic material, a magnetic field can be applied to the particles to affect the extent of conductivity. The magnetic field can be varied to adjust the conductivity of the particles (and, therefore,
30 to adjust the extent of heating and ablation).

In some embodiments in which material 14 is a ferromagnetic material, the particles can be used in an agitation ablation process. In such a process, a magnetic

field can be used to agitate the particles, such that the particles heat and/or physically deform the surrounding tissue, thereby ablating the surrounding tissue.

In some embodiments, material 14 is formed of one or more radiopaque materials. As used herein, a radiopaque material refers to a material having a density of about ten grams per cubic centimeter or greater (e.g., about 25 grams per cubic centimeter or greater, about 50 grams per cubic centimeter or greater). A radiopaque material can be, for example, a metal (e.g., tungsten, tantalum, platinum, palladium, lead, gold, titanium, silver), a metal alloy (e.g., stainless steel, an alloy of tungsten, an alloy of tantalum, an alloy of platinum, an alloy of palladium, an alloy of lead, an alloy of gold, an alloy of titanium, an alloy of silver), a metal oxide (e.g., titanium dioxide, zirconium oxide, aluminum oxide), bismuth subcarbonate, or barium sulfate. In some embodiments, a radiopaque material is a radiopaque contrast agent. Examples of radiopaque contrast agents include Omnipaque™, Renocal®, iodamide meglumine, diatrizoate meglumine, ipodate calcium, ipodate sodium, iodamide sodium, iothalamate sodium, iopamidol, and metrizamide. Radiopaque contrast agents are commercially available from, for example, Bracco Diagnostic.

In embodiments in which material 14 is formed of one or more radiopaque materials, particle 10 can exhibit enhanced visibility under X-ray fluoroscopy, such as when particle 10 is in a subject (see discussion below). In some embodiments, X-ray fluoroscopy can be performed without the use of a radiopaque contrast agent.

In some embodiments, material 14 can include one or more MRI-visible materials. As used herein, a MRI-visible material refers to a material that has a magnetic susceptibility of at most about one or less (e.g., at most about 0.5 or less; at most about zero or less) when measured at 25°C. An MRI-visible material can be, for example, a non-ferrous metal-alloy containing paramagnetic elements (e.g., dysprosium or gadolinium) such as terbium-dysprosium, dysprosium, and gadolinium; a non-ferrous metallic band coated with an oxide or a carbide layer of dysprosium or gadolinium (e.g., Dy₂O₃ or Gd₂O₃); a non-ferrous metal (e.g., copper, silver, platinum, or gold) coated with a layer of superparamagnetic material, such as nanocrystalline Fe₃O₄, CoFe₂O₄, MnFe₂O₄, or MgFe₂O₄; or nanocrystalline particles of the transition metal oxides (e.g., oxides of Fe, Co, Ni). In some embodiments in which material 14 is formed of a ferromagnetic material, material 14 can also serve as an MRI-visible

material if material 14 is present in a sufficiently low concentration. In some
embodiments, an MRI-visible material can be an MRI contrast agent. Examples of
MRI contrast agents include superparamagnetic iron oxides (e.g., ferumoxides,
ferucarbotran, ferumoxsil, ferumoxtran (e.g., ferumoxtran-10), PEG-feron,
5 ferucarbotran); gadopentetate dimeglumine; gadoterate meglumine; gadodiamide;
gadoteridol; gadoversetamide; gadobutrol; gadobenate dimeglumine; mangafodipir
trisodium; gadoxetic acid; gadobenate dimeglumine; macromolecular Gd-DOTA
derivate; gadobenate dimeglumine; gadopentetate dimeglumine; ferric ammonium
citrate; manganese chloride; manganese-loaded zeolite; ferristene; perfluoro-
10 octylbromide; and barium sulfate. MRI contrast agents are described, for example, in
U.S. Patent Application No. 10/390,202, filed on March 17, 2003, and entitled
"Medical Devices", which is incorporated herein by reference.

In embodiments in which material 14 is formed of one or more MRI-visible
materials, particle 10 can exhibit enhanced visibility using MRI, such as when particle
15 10 is in a subject (see discussion below). In some embodiments, MRI can be
performed without the use of an MRI contrast agent.

In certain embodiments, material 14 can be biocompatible. As an example,
material 14 can be a biocompatible ferromagnetic material (e.g., magnetite). As
another example, material 14 can be a biocompatible radiopaque material (e.g.,
20 magnetite). As an additional example, material 14 can be a biocompatible MRI-
visible material (e.g., magnetite, gadolinium).

In some embodiments, material 14 can be bioerodable, such that material 14
can eventually break down in the body and either be dispersed throughout the body or
excreted from the body. For example, material 14 can be a bioerodable ferromagnetic
25 material. In such cases, material 14 may interfere with MRI-visibility when used in
the body in a high concentration and/or a condensed form (e.g., when used in a
particle). However, as material 14 is bioeroded and dispersed throughout the body or
excreted from the body, its interference with MRI-visibility can decrease. Thus, a
bioerodable ferromagnetic material 14 can be used, for example, for short-term
30 embolic applications, without permanently interfering with MRI-visibility.

In some embodiments, both material 14 and matrix 12 can be biocompatible. For example, matrix 12 can be a polysaccharide (e.g., alginate), while material 14 is a biocompatible material (e.g., magnetite).

Generally, the amount of material 14 contained within particle 10 can be varied as desired. In some embodiments, particle 10 can include more than about 0.1 percent by weight (e.g., more than about 0.5 percent by weight, more than about one percent by weight, more than about five percent by weight, more than about ten percent by weight, more than about 20 percent by weight, more than about 30 percent by weight, more than about 40 percent by weight, more than about 50 percent by weight, more than about 60 percent by weight, more than about 70 percent by weight, more than about 80 percent by weight) and/or less than about 90 percent by weight (e.g., less than about 80 percent by weight, less than about 70 percent by weight, less than about 60 percent by weight, less than about 50 percent by weight, less than about 40 percent by weight, less than about 30 percent by weight, less than about 20 percent by weight, less than about ten percent by weight, less than about five percent by weight, less than about one percent by weight, less than about 0.5 percent by weight) of material 14.

In certain embodiments in which material 14 includes one or more ferromagnetic materials, particle 10 can include from about 0.1 percent by weight to about 90 percent by weight (e.g., from about 0.1 percent by weight to about 75 percent by weight, from about 0.1 percent by weight to about 50 percent by weight, from about one percent by weight to about 25 percent by weight) of the ferromagnetic material(s).

In some embodiments in which material 14 includes one or more radiopaque materials, particle 10 can include from about 0.1 percent by weight to about 50 percent by weight (e.g., from about 0.1 percent by weight to about 20 percent by weight, from about one percent by weight to about 20 percent by weight) of the radiopaque material(s).

In certain embodiments in which material 14 includes one or more MRI-visible materials, particle 10 can include from about five percent by weight to about 50 percent by weight (e.g., from about ten percent by weight to about 30 percent by weight) of the MRI-visible material(s).

In general, material 14 can be in any desired form (e.g., a solid, a liquid) and any desired shape (e.g., one or more particles, one or more fibers, one or more flakes, and/or one or more powders). In some embodiments, material 14 (e.g., a particle of material 14, a fiber of material 14, a flake of material 14, a powder of material 14) can have a width or diameter, and/or length, of less than about 40 microns (e.g., less than about 35 microns, less than about 30 microns, less than about 25 microns, less than about 20 microns, less than about 15 microns, less than about ten microns, less than about five microns, less than about one micron, less than about 0.5 micron, less than about 0.1 micron, less than about 0.05 micron, less than about 0.03 micron, less than about 0.01 micron) and/or more than about 0.005 micron (e.g., more than about 0.01 micron, more than about 0.03 micron, more than about 0.05 micron, more than about 0.1 micron, more than about 0.5 micron, more than about one micron, more than about five microns, more than about ten microns, more than about 15 microns, more than about 20 microns, more than about 25 microns, more than about 30 microns, more than about 35 microns). In some embodiments, material 14 (e.g., a particle of material 14, a fiber of material 14, a flake of material 14, a powder of material 14) can have a width or diameter, and/or a length, of from about two microns to about 20 microns (e.g., from about ten microns to about 12 microns).

As used herein, a fiber of material 14 has a ratio of its largest linear dimension to its smallest linear dimension of at least about 2:1 (e.g., at least about 3:1, at least about 5:1, at least about 10:1, at least about 15:1). In some embodiments, a fiber of material 14 has a ratio of its largest linear dimension to its smallest linear dimension of at most about 20:1 (e.g., at most about 15:1, at most about 10:1, at most about 5:1, at most about 3:1). In some embodiments, material 14 includes a mixture of fibers having two or more different aspect ratios.

In general, various methods can be used to prepare particle 10. In some embodiments, particle 10 is formed using a drop generator.

FIG. 2A shows an embodiment of a system for producing particle 10. The system includes a flow controller 300, a drop generator 310, a gelling vessel 320, a reactor vessel 330, a gel dissolution chamber 340 and a filter 350. As shown in FIG. 2B, flow controller 300 delivers a solution that contains the material of matrix 12 (e.g., one or more polymers) and a gelling precursor (e.g., alginate) to a viscosity

controller 305, which heats the solution to reduce viscosity prior to delivery to drop generator 310. The solution passes through an orifice in a nozzle in drop generator 310, forming drops of the solution. The drops are then directed into gelling vessel 320, where the drops contact a gelling agent (e.g., calcium chloride) and are stabilized by gel formation. The gel-stabilized drops are transferred from gelling vessel 320 to reactor vessel 330, where the polymer in the gel-stabilized drops is reacted (e.g., cross-linked), forming precursor particles. The precursor particles are transferred to gel dissolution chamber 340, where the gelling precursor is removed. The particles are then filtered in filter 350 to remove debris, and are sterilized and packaged as an embolic composition including the particles. Methods of making particles are described, for example, in U.S. Patent Application No. _____ [Attorney Docket No. 01194-465001], filed on August 8, 2003, and entitled "Embolization", which is incorporated herein by reference.

In some embodiments in which a drop generator is used in the preparation of particle 10, material 14 is included in the solution delivered by the drop generator, and the solution is processed as described above to form particle 10. In certain embodiments in which a drop generator is used in the preparation of particle 10, material 14 is included in the gelling vessel so that material 14 is incorporated into the drop when the drop contacts the gelling agent. Combinations of these methods can be used.

In some embodiments, material 14 is added to particle 10 in a separate operation. For example, material 14 can be applied to the surface of particle 10 by compounding matrix material 12 with one or more of the coating materials (described below) and then applying the compounded coating material to the surface of particle 10. In certain embodiments, material 14 can be placed in particle 10 (e.g., in one or more pores 16 or cavities of particle 10). In embodiments in which material 14 is in liquid form (e.g., a contrast agent) prior to being incorporated into particle 10, material 14 can be incorporated into the particles by, for example, absorption. Combinations of these methods can be used. For example, in some embodiments, one material can be incorporated into a cavity in a particle, while another material (either the same as, or different from, the first material) can be absorbed through the surface of the particle.

In some embodiments, multiple particles are combined with a carrier fluid (e.g., a saline solution, a contrast agent, or both) to form an embolic composition. Such embolic compositions can be used in, for example, neural, pulmonary, and/or AAA (abdominal aortic aneurysm) applications. The compositions can be used in the treatment of, for example, fibroids, tumors, internal bleeding, arteriovenous malformations (AVMs), and/or hypervascular tumors. The compositions can be used as, for example, fillers for aneurysm sacs, AAA sac (Type II endoleaks), endoleak sealants, arterial sealants, and/or puncture sealants, and/or can be used to provide occlusion of other lumens such as fallopian tubes. Fibroids can include uterine fibroids which grow within the uterine wall (intramural type), on the outside of the uterus (subserosal type), inside the uterine cavity (submucosal type), between the layers of broad ligament supporting the uterus (interligamentous type), attached to another organ (parasitic type), or on a mushroom-like stalk (pedunculated type). Internal bleeding includes gastrointestinal, urinary, renal and varicose bleeding. AVMs are for example, abnormal collections of blood vessels, e.g. in the brain, which shunt blood from a high pressure artery to a low pressure vein, resulting in hypoxia and malnutrition of those regions from which the blood is diverted. In some embodiments, a composition containing the particles can be used to prophylactically treat a condition.

The magnitude of a dose of an embolic composition can vary based on the nature, location and severity of the condition to be treated, as well as the route of administration. A physician treating the condition, disease or disorder can determine an effective amount of embolic composition. An effective amount of embolic composition refers to the amount sufficient to result in amelioration of symptoms or a prolongation of survival of the subject. The embolic compositions can be administered as pharmaceutically acceptable compositions to a subject in any therapeutically acceptable dosage, including those administered to a subject intravenously, subcutaneously, percutaneously, intratracheally, intramuscularly, intramucosally, intracutaneously, intra-articularly, orally or parenterally.

An embolic composition can be prepared in calibrated concentrations of the particles for ease of delivery by the physician. Suspensions of the particles in saline solution can be prepared to remain stable (e.g., to not precipitate) over a duration of

time. A suspension of the particles can be stable, for example, for from about one minute to about 20 minutes (e.g. from about one minute to about ten minutes, from about two minutes to about seven minutes, from about three minutes to about six minutes). The concentration of particles can be determined by adjusting the weight ratio of the particles to the physiological solution. If the weight ratio of the particles is too small, then too much liquid could be injected into a blood vessel, possibly allowing the particles to stray into lateral vessels. In some embodiments, the physiological solution can contain from about 0.01 weight percent to about 15 weight percent of the particles. A composition can include a mixture of particles, such as particles including ferromagnetic material, and particles including radiopaque material.

Referring to FIGS. 3A and 3B, an embolic composition, including embolic particles 111 and a carrier fluid, is injected into a vessel through an instrument such as a catheter 150. Catheter 150 is connected to a syringe barrel 110 with a plunger 160. Catheter 150 is inserted, for example, into a femoral artery 120 of a subject. Catheter 150 delivers the embolic composition to, for example, occlude a uterine artery 130 leading to a fibroid 140. Fibroid 140 is located in the uterus of a female subject. The embolic composition is initially loaded into syringe 110. Plunger 160 of syringe 110 is then compressed to deliver the embolic composition through catheter 150 into a lumen 165 of uterine artery 130.

Referring particularly to FIG. 3B, which is an enlarged view of section 3B of FIG. 3A, uterine artery 130 is subdivided into smaller uterine vessels 170 (e.g., having a diameter of about two millimeters or less) which feed fibroid 140. The embolic particles 111 in the embolic composition partially or totally fill the lumen of uterine artery 130, either partially or completely occluding the lumen of the uterine artery 130 that feeds uterine fibroid 140.

In some embodiments, among the particles delivered to a subject in an embolic composition, the majority (e.g., about 50 percent or more, about 60 percent or more, about 70 percent or more, about 80 percent or more, about 90 percent or more) of the particles have a diameter of about 3,000 microns or less (e.g., about 2,500 microns or less; about 2,000 microns or less; about 1,500 microns or less; about 1,200 microns or less; about 900 microns or less; about 700 microns or less; about 500

microns or less; about 400 microns or less; about 300 microns or less; about 100 microns or less) and/or about ten microns or more (e.g., about 100 microns or more; about 300 microns or more; about 400 microns or more; about 500 microns or more; about 700 microns or more; about 900 microns or more; about 1,200 microns or more; about 1,500 microns or more; about 2,000 microns or more; about 2,500 microns or more).

In certain embodiments, the particles delivered to a subject in an embolic composition have a mean diameter of about 3,000 microns or less (e.g., about 2,500 microns or less; about 2,000 microns or less; about 1,500 microns or less; about 1,200 microns or less; about 900 microns or less; about 700 microns or less; about 500 microns or less; about 400 microns or less; about 300 microns or less; about 100 microns or less) and/or about ten microns or more (e.g., about 100 microns or more; about 300 microns or more; about 400 microns or more; about 500 microns or more; about 700 microns or more; about 900 microns or more; about 1,200 microns or more; about 1,500 microns or more; about 2,000 microns or more; about 2,500 microns or more). Exemplary ranges for the mean diameter of particles delivered to a subject include from about 100 microns to about 300 microns; from about 300 microns to about 500 microns; from about 500 microns to about 700 microns; and from about 900 microns to about 1,200 microns. In general, the particles delivered to a subject in an embolic composition have a mean diameter in approximately the middle of the range of the diameters of the individual particles, and a variance of about 20 percent or less (e.g. about 15 percent or less, about ten percent or less).

In some embodiments, the mean size of the particles delivered to a subject in an embolic composition can vary depending upon the particular condition to be treated. As an example, in embodiments in which the particles in an embolic composition are used to treat a liver tumor, the particles delivered to the subject can have a mean diameter of about 500 microns or less (e.g., from about 100 microns to about 300 microns; from about 300 microns to about 500 microns). As another example, in embodiments in which the particles in an embolic composition are used to treat a uterine fibroid, the particles delivered to the subject in an embolic composition can have a mean diameter of about 1,200 microns or less (e.g., from about 500

microns to about 700 microns; from about 700 microns to about 900 microns; from about 900 microns to about 1,200 microns).

While certain embodiments have been described, the invention is not so limited.

5 As an example, in some embodiments, a particle can contain combinations of different types of materials (e.g., one or more ferromagnetic materials and one or more radiopaque materials; one or more radiopaque materials and one or more MRI-visible materials; one or more ferromagnetic materials and one or more MRI-visible materials; one or more MRI-visible materials, one or more ferromagnetic materials, and one or more radiopaque materials).

10 As another example, a particle can be prepared (e.g., for use in an embolic composition) without removal of the gelling precursor (e.g. alginate). Such particles can be prepared, for example, using a drop generator as described above, but without removing the gelling precursor from the particle after cross-linking.

15 As an additional example, in some embodiments a particle can include one or more therapeutic agents (e.g., drugs). The therapeutic agent(s) can be in and/or on the particle. Therapeutic agents include agents that are negatively charged, positively charged, amphoteric, or neutral. Therapeutic agents can be, for example, materials that are biologically active to treat physiological conditions; pharmaceutically active
20 compounds; gene therapies; nucleic acids with and without carrier vectors; oligonucleotides; gene/vector systems; DNA chimeras; compacting agents (e.g., DNA compacting agents); viruses; polymers; hyaluronic acid; proteins (e.g., enzymes such as ribozymes); cells (of human origin, from an animal source, or genetically engineered); stem cells; immunologic species; nonsteroidal anti-inflammatory
25 medications; oral contraceptives; progestins; gonadotrophin-releasing hormone agonists; chemotherapeutic agents; and radioactive species (e.g., radioisotopes, radioactive molecules). Non-limiting examples of therapeutic agents include anti-thrombogenic agents; antioxidants; angiogenic and anti-angiogenic agents and factors; anti-proliferative agents (e.g., agents capable of blocking smooth muscle cell
30 proliferation); anti-inflammatory agents; calcium entry blockers; antineoplastic/antiproliferative/anti-mitotic agents (e.g., paclitaxel, doxorubicin, cisplatin); antimicrobials; anesthetic agents; anti-coagulants; vascular cell growth

promoters; vascular cell growth inhibitors; cholesterol-lowering agents; vasodilating agents; agents which interfere with endogenous vasoactive mechanisms; and survival genes which protect against cell death. Therapeutic agents are described, for example, in co-pending U.S. Patent Application No. 10/615,276, filed on July 8, 2003, and entitled "Agent Delivery Particle", which is incorporated herein by reference.

As a further example, in some embodiments a particle can be coated (e.g., with a bioabsorbable material). For example, a particle can include a polyvinyl alcohol matrix polymer with a sodium alginate coating. The coating can contain, for example, one or more therapeutic agents. In certain embodiments, a particle can be coated to include a high concentration of one or more therapeutic agents and/or loaded into the interior of the particle. The surface can release an initial dosage of therapeutic agent after which the body of the particle can provide a burst release of therapeutic agent. The therapeutic agent on the surface can be the same as or different from the therapeutic agent in the body of the particle. The therapeutic agent on the surface can be applied by exposing the particle to a high concentration solution of the therapeutic agent. The therapeutic agent coated particle can include another coating over the surface the therapeutic agent (e.g., a degradable and/or bioabsorbable polymer which erodes when the particle is administered). The coating can assist in controlling the rate at which therapeutic agent is released from the particle. For example, the coating can be in the form of a porous membrane. The coating can delay an initial burst of therapeutic agent release. The coating can be applied by dipping or spraying the particle. The erodible polymer can be a polysaccharide (such as an alginate). In some embodiments, the coating can be an inorganic, ionic salt. Other erodible coatings include water soluble polymers (such as polyvinyl alcohol, e.g., that has not been cross-linked), biodegradable poly DL-lactide-poly ethylene glycol (PELA), hydrogels (e.g., polyacrylic acid, haluronic acid, gelatin, carboxymethyl cellulose), polyethylene glycols (PEG), chitosan, polyesters (e.g., polycaprolactones), and poly(lactic-co-glycolic) acids (e.g., poly(d-lactic-co-glycolic) acids). The coating can include therapeutic agent or can be substantially free of therapeutic agent. The therapeutic agent in the coating can be the same as or different from an agent on a surface layer of the particle and/or within the particle. A polymer coating, e.g. an erodible coating,

can be applied to the particle surface in cases in which a high concentration of therapeutic agent has not been applied to the particle surface. In some embodiments, the coating can include a ferromagnetic material, a radiopaque material, and/or an MRI-visible material. Alternatively or in addition, the particle interior can include a ferromagnetic material, a radiopaque material, and/or an MRI-visible material. The coating can include a higher, equal, or lower concentration of ferromagnetic material, radiopaque material, and/or MRI-visible material relative to the particle interior. In some embodiments, the interior of the particle can include one type of material (e.g., a ferromagnetic material), while the coating includes a different type of material (e.g., a radiopaque material). Coatings are described, for example, in U.S. Patent Application No. 10/615,276, filed on July 8, 2003, and entitled "Agent Delivery Particle", which is incorporated herein by reference.

As an additional example, in some embodiments one or more particles is/are substantially nonspherical. In some embodiments, particles can be shaped (e.g., molded, compressed, punched, and/or agglomerated with other particles) at different points in the particle manufacturing process. In some embodiments (e.g., where the matrix polymer is a polyvinyl alcohol and the gelling precursor is sodium alginate), after contacting the particles with the gelling agent but before cross-linking, the particles can be physically deformed into a specific shape and/or size. After shaping, the matrix polymer (e.g., polyvinyl alcohol) can be cross-linked, optionally followed by substantial removal of the gelling precursor (e.g., alginate). While substantially spherical particles are preferred, non-spherical particles can be manufactured and formed by controlling, for example, drop formation conditions. In some embodiments, nonspherical particles can be formed by post-processing the particles (e.g., by cutting or dicing into other shapes). Particle shaping is described, for example, in co-pending U.S. Patent Application No. 10/402,068, filed March 28, 2003, and entitled "Forming a Chemically Cross-Linked Particle of a Desired Shape and Diameter", which is incorporated herein by reference.

As a further example, in some embodiments the particles can be used for tissue bulking. As an example, the particles can be placed (e.g., injected) into tissue adjacent to a body passageway. The particles can narrow the passageway, thereby providing bulk and allowing the tissue to constrict the passageway more easily. The

particles can be placed in the tissue according to a number of different methods, for example, percutaneously, laparoscopically, and/or through a catheter. In certain embodiments, a cavity can be formed in the tissue, and the particles can be placed in the cavity. Particle tissue bulking can be used to treat, for example, intrinsic
5 sphincteric deficiency (ISD), vesicoureteral reflux, gastroesophageal reflux disease (GERD), and/or vocal cord paralysis (e.g., to restore glottic competence in cases of paralytic dysphonia). In some embodiments, particle tissue bulking can be used to treat urinary incontinence and/or fecal incontinence. The particles can be used as a graft material or a filler to fill and/or to smooth out soft tissue defects, such as for
10 reconstructive or cosmetic applications (e.g., surgery). Examples of soft tissue defect applications include cleft lips, scars (e.g., depressed scars from chicken pox or acne scars), indentations resulting from liposuction, wrinkles (e.g., glabella frown wrinkles), and soft tissue augmentation of thin lips. Tissue bulking is described, for example, in co-pending U.S. Patent Application No. 10/231,664, filed on August 30,
15 2002, and entitled "Tissue Treatment", which is incorporated herein by reference.

As an additional example, in certain embodiments one or more ferromagnetic materials, one or more MRI-visible materials and/or one or more radiopaque materials can be nonhomogeneously distributed in a particle. As an example, the density of the ferromagnetic, MRI-visible and/or radiopaque material(s) can be higher in the center
20 region of the particle than at the surface region of the particle. As another example, the density of the ferromagnetic, MRI-visible and/or radiopaque material(s) can be higher at the surface region of the particle than in the center region of the particle.

As another example, in certain embodiments a particle can have a cavity (a portion that is substantially devoid of a matrix material such as a matrix polymer) that
25 has a diameter of at least about 50 microns (e.g., at least about 100 microns, at least about 150 microns). In some embodiments, such a cavity can contain one or more ferromagnetic materials, one or more MRI-visible materials and/or one or more radiopaque materials. In such embodiments, the ferromagnetic, MRI-visible and/or radiopaque material(s) can be nonhomogeneously distributed in the particle.

30 As a further example, in some embodiments one or more ferromagnetic materials, one or more MRI-visible materials and/or one or more radiopaque materials can be located at the surface of the particle. In such embodiments, the interior of the

particle can be substantially devoid the ferromagnetic, MRI-visible and/or radiopaque material(s), or the interior of the particle can further include the ferromagnetic, MRI-visible and/or radiopaque material(s).

5 As an additional example, in certain embodiments one or more ferromagnetic materials, one or more MRI-visible materials and/or one or more radiopaque materials can be attached to the surface of a particle (e.g., via a chemical linker).

 As another example, in some embodiments a particle can be formed with no pores and/or no cavities.

10 As a further example, in some embodiments a particle can be formed without pores (nonporous particle).

 Other embodiments are in the claims.

WHAT IS CLAIMED IS:

1. A particle, comprising a polymeric matrix and a ferromagnetic material distributed in the polymeric matrix, wherein the particle has a diameter of from about ten microns to about 3,000 microns.

5 2. The particle of claim 1, wherein the ferromagnetic material is selected from the group consisting of transition metals, metal alloys, and metal oxides.

 3. The particle of claim 1, wherein the ferromagnetic material is selected from the group consisting of magnetite, nickel, cobalt, iron and Mu-metal.

10 4. The particle of claim 1, wherein the ferromagnetic material comprises magnetite.

 5. The particle of claim 1, wherein the ferromagnetic material is selected from the group consisting of soft ferrites, rare-earth magnet alloys, and amorphous and non-earth alloys.

 6. The particle of claim 1, wherein the ferromagnetic material is in the shape of at least one article selected from the group consisting of particles, fibers, flakes, and powders.

 7. The particle of claim 6, wherein the article has a diameter of from about two microns to about 20 microns.

25 8. The particle of claim 1, wherein the ferromagnetic material is substantially homogeneously distributed throughout the polymeric matrix.

 9. The particle of claim 1, wherein the polymeric matrix comprises a polysaccharide.

30

10. The particle of claim 1, wherein the polymeric matrix comprises a member selected from the group consisting of polyvinyl alcohols, polyacrylic acids, polymethacrylic acids, poly vinyl sulfonates, carboxymethyl celluloses, hydroxyethyl celluloses, substituted celluloses, polyacrylamides, polyethylene glycols, polyamides, 5 polyureas, polyurethanes, polyesters, polyethers, polystyrenes, polysaccharides, polylactic acids, polyethylenes, polymethylmethacrylates, polycaprolactones, polyglycolic acids, poly(lactic-co-glycolic) acids, and combinations thereof.

11. The particle of claim 1, wherein the particle further comprises a 10 therapeutic agent.

12. The particle of claim 1, wherein the polymeric matrix comprises a first polymer and a second polymer.

13. The particle of claim 12, wherein the second polymer forms a coating 15 over the first polymer.

14. The particle of claim 1, wherein the particle is substantially spherical.

15. The particle of claim 1, wherein the particle contains pores. 20

16. The particle of claim 1, wherein the particle has an interior with a density of large pores and a surface region with a density of large pores, and the density of large pores of the interior is greater than the density of large pores of the 25 surface region.

17. The particle of claim 1, wherein the particle comprises from about 0.1 percent to about 90 percent by weight of the ferromagnetic material.

18. The particle of claim 1, wherein the polymeric matrix has a coating 30 comprising an inorganic, ionic salt.

19. A particle, comprising a polymeric matrix and a radiopaque material distributed in the polymeric matrix, wherein the particle has a diameter of from about ten microns to about 3,000 microns, and wherein the particle has an interior with a density of large pores and a surface region with a density of large pores, and the density of large pores of the interior is greater than the density of large pores of the surface region.

20. The particle of claim 19, wherein the radiopaque material is selected from the group consisting of metals, metal alloys, and contrast agents.

21. The particle of claim 19, wherein the radiopaque material comprises a member selected from the group consisting of titanium dioxide and bismuth subcarbonate.

22. The particle of claim 19, wherein the radiopaque material comprises platinum or barium sulfate.

23. The particle of claim 19, wherein the radiopaque material is substantially homogeneously distributed throughout the polymeric matrix.

24. The particle of claim 19, wherein the polymeric matrix comprises a polysaccharide.

25. The particle of claim 19, wherein the polymeric matrix comprises a member selected from the group consisting of polyvinyl alcohols, polyacrylic acids, polymethacrylic acids, poly vinyl sulfonates, carboxymethyl celluloses, hydroxyethyl celluloses, substituted celluloses, polyacrylamides, polyethylene glycols, polyamides, polyureas, polyurethanes, polyesters, polyethers, polystyrenes, polysaccharides, polylactic acids, polyethylenes, polymethylmethacrylates, polycaprolactones, polyglycolic acids, poly(lactic-co-glycolic) acids, and combinations thereof.

26. The particle of claim 19, wherein the particle further comprises a therapeutic agent.

27. The particle of claim 19, wherein the polymeric matrix comprises a first polymer and a second polymer.

28. The particle of claim 27, wherein the second polymer forms a coating over the first polymer.

29. The particle of claim 19, wherein the particle is substantially spherical.

30. The particle of claim 19, wherein the particle comprises from about 0.1 percent to about 50 percent by weight of the radiopaque material.

31. A particle, comprising a polymeric matrix and a material distributed in the polymeric matrix, wherein the material is visible by magnetic resonance imaging, and the particle has a diameter of from about ten microns to about 3,000 microns, and wherein the particle has an interior with a density of large pores and a surface region with a density of large pores, and the density of large pores of the interior is greater than the density of large pores of the surface region.

32. The particle of claim 31, wherein the material is selected from the group consisting of non-ferrous metal-alloys containing paramagnetic elements; non-ferrous metallic bands coated with an oxide or a carbide layer of dysprosium or gadolinium; non-ferrous metals coated with a layer of superparamagnetic material; and nanocrystalline particles of the transition metal oxides.

33. The particle of claim 31, wherein the material is selected from the group consisting of terbium-dysprosium, dysprosium, gadolinium, Dy_2O_3 , and Gd_2O_3 .

34. The particle of claim 31, wherein the material comprises gadolinium.

35. The particle of claim 31, wherein the polymeric matrix comprises a polysaccharide.

36. The particle of claim 31, wherein the polymeric matrix comprises a
5 member selected from the group consisting of polyvinyl alcohols, polyacrylic acids, polymethacrylic acids, poly vinyl sulfonates, carboxymethyl celluloses, hydroxyethyl celluloses, substituted celluloses, polyacrylamides, polyethylene glycols, polyamides, polyureas, polyurethanes, polyesters, polyethers, polystyrenes, polysaccharides, polylactic acids, polyethylenes, polymethylmethacrylates, polycaprolactones,
10 polyglycolic acids, poly(lactic-co-glycolic) acids, and combinations thereof.

37. The particle of claim 31, wherein the particle further comprises a therapeutic agent.

15 38. The particle of claim 31, wherein the particle is substantially spherical.

39. The particle of claim 31, wherein the particle comprises from about five percent to about 50 percent by weight of the material.

20 40. A method, comprising:
heating a plurality of particles disposed in a body lumen,
wherein the particles comprise a polymeric matrix and a ferromagnetic material distributed in the polymeric matrix, and wherein the particles have a diameter of from about ten microns to about 3,000 microns.

25 41. The method of claim 40, wherein the method ablates body tissue.

42. The method of claim 40, wherein heating the particles comprises exposing the particles to RF radiation.

30 43. The method of claim 40, wherein heating the particles heats body tissue.

Appendix A.

5. DEFINITIONS OF VARIABLES

5.1 STATISTICAL MEASURES

Averages:

Arithmetic mean: $\sum D_k / N$ Average diameter of all the particles in the sample.

Surface mean: $[\sum D_k^2 / N]^{1/2}$ The diameter of a particle whose surface area, if multiplied by the total number of particles, will equal the total surface area of the sample.

Volume mean: $[\sum D_k^3 / N]^{1/3}$ The diameter of a particle whose volume, if multiplied by the total number of particles, equals the total volume of the sample.

Sauter mean: $\sum D_k^3 / \sum D_k^2$ The diameter of a particle whose ratio of volume to surface area is the same as the complete sample.

Sample size check: $\sum D_{max}^3 / \sum D_k^3$ Fraction of the total volume represented by the largest particle.

Percentiles:

DVXX: the XXth percentile by volume. It is computed as the diameter such that the collection of particles having that size or less represents XX % of the total volume. The commonly used ones are DV10, DV50 and DV90.

DV50 is also called the volume median. It is the diameter that divides the sample into two equal halves, by mass or volume.

Measures of spread:

Deviation:
$$\frac{\sum [(D_{obs} - (D_{klb} + D_{kub}) / 2) N_k]^2}{\sum N_k D_{0.5}}$$


$$D_{klb} = \text{lower bound of bin } k$$

$$D_{kub} = \text{upper bound of bin } k$$

Relative span:
$$\frac{D_{0.9} - D_{0.1}}{D_{0.5}}$$

Sphericity: a value from 0 to 1, with 1 representing a perfect circle. Computed as D_a / D_p , where $D_a = \text{square root}(4 A / \pi)$, $D_p = P / \pi$; A = pixel area, P = pixel perimeter.

Best Available Copy






FIG. 2A

3/5




FIG. 2B

4/5




FIG. 3A

5/5




FIG. 3B

INTERNATIONAL SEARCH REPORT

Intern: Application No
PCT/US 03/27358

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61L24/00 A61L24/02 A61L27/50 A61L31/18 A61L31/14 A61L31/02 A61K49/18		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 A61L A61F A61K A61N		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, PAJ		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 6 315 709 B1 (GARIBALDI JEFF ET AL) 13 November 2001 (2001-11-13) claims ---	1-43
X	US 2001/051670 A1 (ASFAW BRUKTAWIT T ET AL) 13 December 2001 (2001-12-13) page 7, line 1 - line 18; claims ---	1-43
X	WO 02 11696 A (EV & M) 14 February 2002 (2002-02-14) page 13, line 1 - line 4; claims ---	1-43
X	US 5 695 480 A (EVANS SCOTT ET AL) 9 December 1997 (1997-12-09) column 5, line 62 - column 6, line 6; claims --- -/--	1-43
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family		
Date of the actual completion of the international search 5 February 2004		Date of mailing of the international search report 16/02/2004
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040. Tx. 31 651 epo nl. Fax: (+31-70) 340-3016		Authorized officer ESPINOSA, M

INTERNATIONAL SEARCH REPORT

Intern
Application No
PCT/US 03/27358

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 600 529 A (STERLING WINTHROP INC) 8 June 1994 (1994-06-08) claims; examples ----	1-43
E	WO 03 082359 A (CASEY THOMAS V II ;SCIMED LIFE SYSTEMS INC (US); BOURNE GEORGE (US) 9 October 2003 (2003-10-09) page 19, line 14 - line 31; claims ----	1-43
A	US 5 262 176 A (JOSEPHSON LEE ET AL) 16 November 1993 (1993-11-16) claims; examples 1-4 ----	1-43
A	US 6 224 630 B1 (YUAN HANSEN A ET AL) 1 May 2001 (2001-05-01) column 10, line 51 - line 67; claims ----	1-43
A	US 5 698 271 A (RAO GALLA C ET AL) 16 December 1997 (1997-12-16) claims; examples -----	1-43

INTERNATIONAL SEARCH REPORT

Information on patent family members

Internal application No
PCT/US 03/27358

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 6315709	B1	13-11-2001	AU 3894100 A 04-10-2000
			AU 3898300 A 04-10-2000
			EP 1169081 A1 09-01-2002
			WO 0054835 A1 21-09-2000
			WO 0054832 A1 21-09-2000
			US 6375606 B1 23-04-2002
			US 6296604 B1 02-10-2001
			US 6364823 B1 02-04-2002
			AU 5548299 A 28-02-2000
			EP 1115327 A2 18-07-2001
			WO 0007641 A2 17-02-2000
			US 6522909 B1 18-02-2003
US 2001051670	A1	13-12-2001	US 2003211073 A1 13-11-2003
			AU 4360301 A 24-09-2001
			AU 4361601 A 24-09-2001
			AU 4566001 A 24-09-2001
			CA 2402773 A1 20-09-2001
			CA 2402774 A1 20-09-2001
			CA 2403218 A1 20-09-2001
			EP 1263801 A1 11-12-2002
			EP 1263802 A1 11-12-2002
			EP 1263803 A1 11-12-2002
			JP 2003527402 T 16-09-2003
			JP 2003527172 T 16-09-2003
			JP 2003527173 T 16-09-2003
			WO 0168720 A1 20-09-2001
			WO 0168721 A1 20-09-2001
			WO 0168722 A1 20-09-2001
			US 2003223956 A1 04-12-2003
			US 2001036451 A1 01-11-2001
			US 2001056301 A1 27-12-2001
WO 0211696	A	14-02-2002	WO 0211696 A2 14-02-2002
			US 2003153806 A1 14-08-2003
US 5695480	A	09-12-1997	AU 2814697 A 20-02-1998
			CA 2260047 A1 05-02-1998
			EP 0923399 A1 23-06-1999
			JP 2000517298 T 26-12-2000
			WO 9804312 A1 05-02-1998
EP 0600529	A	08-06-1994	US 5349957 A 27-09-1994
			AU 4747193 A 16-06-1994
			CA 2107280 A1 03-06-1994
			CZ 9302601 A3 17-08-1994
			EP 0600529 A2 08-06-1994
			FI 935302 A 03-06-1994
			HU 69399 A2 28-09-1995
			JP 6218271 A 09-08-1994
			MX 9306009 A1 31-01-1995
			NO 934270 A 03-06-1994
			NZ 248701 A 26-09-1995
			SK 135093 A3 07-09-1994
WO 03082359	A	09-10-2003	US 2003183962 A1 02-10-2003
			US 2003233150 A1 18-12-2003
			WO 03084582 A1 16-10-2003

INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern:

Application No

PCT/US 03/27358

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 03082359	A		WO 03082359 A1	09-10-2003
			WO 03082250 A1	09-10-2003
			WO 03082360 A1	09-10-2003
			US 2003185896 A1	02-10-2003
			WO 03084505 A2	16-10-2003
			US 2003203985 A1	30-10-2003
<hr/>				
US 5262176	A	16-11-1993	US 4827945 A	09-05-1989
			US 5160726 A	03-11-1992
			US 4770183 A	13-09-1988
			AT 143604 T	15-10-1996
			CA 1301063 C	19-05-1992
			DE 3751918 D1	07-11-1996
			DE 3751918 T2	20-03-1997
			EP 0275285 A1	27-07-1988
			JP 1500196 T	26-01-1989
			NO 880931 A	02-03-1988
			US 5490991 A	13-02-1996
			WO 8800060 A1	14-01-1988
			US 5055288 A	08-10-1991
			US 5554386 A	10-09-1996
			US 5589591 A	31-12-1996
			US 5679323 A	21-10-1997
			US 5141739 A	25-08-1992
			US 5284646 A	08-02-1994
			US 5248492 A	28-09-1993
			US 5219554 A	15-06-1993
			US 5478576 A	26-12-1995
			US 5352432 A	04-10-1994
			US 5342607 A	30-08-1994
			US 5336506 A	09-08-1994
			US 5314679 A	24-05-1994
			AT 139431 T	15-07-1996
			DE 68926708 D1	25-07-1996
			DE 68926708 T2	31-10-1996
			EP 0381742 A1	16-08-1990
			EP 0670167 A1	06-09-1995
			JP 4501218 T	05-03-1992
			WO 9001295 A1	22-02-1990
			AT 135920 T	15-04-1996
			CA 2075994 A1	16-08-1991
			DE 69118367 D1	02-05-1996
			DE 69118367 T2	08-08-1996
			EP 0514493 A1	25-11-1992
			EP 0707856 A2	24-04-1996
			JP 5503538 T	10-06-1993
			NO 923178 A	16-09-1992
			WO 9112025 A1	22-08-1991
			US 4951675 A	28-08-1990
			US 5069216 A	03-12-1991
			US 5102652 A	07-04-1992
<hr/>				
US 6224630	B1	01-05-2001	AU 4211899 A	13-12-1999
			EP 1091776 A1	18-04-2001
			JP 2002516156 T	04-06-2002
			WO 9961084 A1	02-12-1999
<hr/>				
US 5698271	A	16-12-1997	US 5597531 A	28-01-1997

INTERNATIONAL SEARCH REPORT

Information on patent family members

Internat. Application No.

PCT/US 03/27358

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5698271	A	US 5512332 A	30-04-1996
		CA 2220169 A1	19-12-1996
		EP 0842042 A1	20-05-1998
		JP 11506568 T	08-06-1999
		WO 9640502 A1	19-12-1996
		US 6120856 A	19-09-2000
		AT 137804 T	15-05-1996
		AU 6340390 A	03-04-1991
		CA 2060182 A1	23-02-1991
		DE 69026949 D1	13-06-1996
		DE 69026949 T2	28-11-1996
		EP 0489119 A1	10-06-1992
		JP 5503188 T	27-05-1993
		WO 9102811 A1	07-03-1991
